NCT01607398View on ClinicalTrials.gov

ADOAIR250 Anti-inflammatory Effects in Japanese Subjects With Chronic Obstructive Pulmonary Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

ADOAIR250

250 mcg inhalation, twice daily, from week0 -12.

DRUG

Placebo

Placebo inhalation, twice daily, from week0 -12.

Trial Locations (3)

530-0001

GSK Investigational Site, Osaka

545-8586

GSK Investigational Site, Osaka

559-0011

GSK Investigational Site, Osaka

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01607398 - ADOAIR250 Anti-inflammatory Effects in Japanese Subjects With Chronic Obstructive Pulmonary Disease | Biotech Hunter | Biotech Hunter